PL314120A1 - B-adrenergic antagonists - Google Patents
B-adrenergic antagonistsInfo
- Publication number
- PL314120A1 PL314120A1 PL96314120A PL31412096A PL314120A1 PL 314120 A1 PL314120 A1 PL 314120A1 PL 96314120 A PL96314120 A PL 96314120A PL 31412096 A PL31412096 A PL 31412096A PL 314120 A1 PL314120 A1 PL 314120A1
- Authority
- PL
- Poland
- Prior art keywords
- adrenergic antagonists
- adrenergic
- antagonists
- Prior art date
Links
- 239000000674 adrenergic antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002220399A CA2220399A1 (en) | 1995-05-10 | 1995-05-10 | .beta.-adrenergic agonists |
PCT/IB1995/000344 WO1996035671A1 (en) | 1995-05-10 | 1995-05-10 | β-ADRENERGIC AGONISTS |
HU9601240A HUP9601240A1 (en) | 1995-05-10 | 1996-05-09 | Pyridin and pyrimidin derivatives, suitable as beta-adrenerg agonists, pharmaceutical compositions containing the same and their intermediates |
Publications (1)
Publication Number | Publication Date |
---|---|
PL314120A1 true PL314120A1 (en) | 1996-11-12 |
Family
ID=89993954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL96314120A PL314120A1 (en) | 1995-05-10 | 1996-05-08 | B-adrenergic antagonists |
Country Status (19)
Country | Link |
---|---|
US (1) | US5977124A (en) |
EP (1) | EP0824519A1 (en) |
JP (1) | JPH11504649A (en) |
KR (1) | KR100190259B1 (en) |
AU (1) | AU706235B2 (en) |
BR (1) | BR9602209A (en) |
CA (1) | CA2220399A1 (en) |
CO (1) | CO4440567A1 (en) |
CZ (1) | CZ132196A3 (en) |
FI (1) | FI974172A (en) |
HU (1) | HUP9601240A1 (en) |
IL (1) | IL118115A0 (en) |
MX (1) | MX9708621A (en) |
NO (1) | NO307049B1 (en) |
NZ (1) | NZ286548A (en) |
PL (1) | PL314120A1 (en) |
SG (1) | SG43365A1 (en) |
TR (1) | TR199600358A2 (en) |
WO (1) | WO1996035671A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981562A (en) * | 1996-01-30 | 1999-11-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6031105A (en) * | 1996-04-09 | 2000-02-29 | Pfizer Inc | Substituted pyridines |
US6008361A (en) * | 1996-04-09 | 1999-12-28 | Pfizer Inc. | Substituted pyridines |
EP0938476B1 (en) * | 1996-11-14 | 2006-03-08 | Pfizer Inc. | Process for substituted pyridines |
US6001856A (en) * | 1997-06-13 | 1999-12-14 | Pfizer Inc. | β-adrenergic agonists to reduce a wasting condition |
EP0920864A1 (en) * | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Combination therapy including a specific beta-3 agonist and an anorectic agent |
US6657063B1 (en) * | 1998-04-30 | 2003-12-02 | Pfizer Inc. | Combinations of β3 agonists and growth hormone secretagogues |
US6090942A (en) * | 1998-10-15 | 2000-07-18 | Pfizer Inc. | Process and intermediates for a β3 -adrenergic receptor agonist |
ATE280167T1 (en) | 1999-07-23 | 2004-11-15 | Pfizer Prod Inc | INTERMEDIATE PRODUCTS AND A METHOD FOR PRODUCING BETA3 ADRENERGIC RECEPTOR AGONISTS |
US7115750B1 (en) | 1999-09-20 | 2006-10-03 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonist |
US6451587B1 (en) | 1999-09-29 | 2002-09-17 | Pfizer Inc. | Microbial asymmetric reduction of 2-chloro-1-[-6-(2,5-dimethyl-pyrrol-1-yl)-pyridin-3-yl]-ethanone |
ES2287120T3 (en) * | 2000-04-28 | 2007-12-16 | Asahi Kasei Pharma Corporation | NEW BICYCLE COMPOUNDS. |
EA200300305A1 (en) * | 2000-10-20 | 2003-08-28 | Пфайзер Продактс Инк. | ALPHA-ARYLETHANOLAMINES AND THEIR APPLICATION AS BETA-ADRENERGIC RECEPTORS AGONISTS |
EP1236723A1 (en) * | 2001-03-01 | 2002-09-04 | Pfizer Products Inc. | Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof |
DOP2003000587A (en) * | 2002-02-27 | 2003-08-30 | Pfizer Prod Inc | Ss3-ADRENERGIC RECEIVER AGONISTS |
AU2003209527A1 (en) | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
AU2003248352A1 (en) | 2002-02-27 | 2003-09-09 | Pfizer Products Inc. | PROCESSES AND INTERMEDIATES USEFUL IN PREPARING Beta3-ADRENERGIC RECEPTOR AGONISTS |
US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
US20050075323A1 (en) * | 2003-03-05 | 2005-04-07 | Pfizer Inc | Beta3 adrenergic receptor agonists and uses thereof |
EP1477167A1 (en) * | 2003-05-15 | 2004-11-17 | Pfizer Limited | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists |
US7375100B2 (en) | 2003-06-04 | 2008-05-20 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
GB0312832D0 (en) * | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
KR101071748B1 (en) * | 2003-12-23 | 2011-10-11 | 아스텔라스세이야쿠 가부시키가이샤 | Aminoalcohol derivatives |
WO2006051373A1 (en) * | 2004-11-12 | 2006-05-18 | Pfizer Limited | Compounds for the treatment of diseases |
AU2006255097B2 (en) | 2005-06-06 | 2012-02-09 | Georgetown University | Compositions and methods for lipo modeling |
BRPI0903206E2 (en) | 2009-09-01 | 2015-07-28 | Da Silva Antonio Carlos Nunes Ett | Diaper and absorbent processing unit and processing method |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4358455A (en) * | 1980-12-23 | 1982-11-09 | Merck & Co., Inc. | Aralkylamindethanol heterocyclic compounds |
DE3278014D1 (en) * | 1982-10-01 | 1988-02-25 | Merck & Co Inc | Aralkylaminoethanol heterocyclic compounds |
CA1287061C (en) * | 1986-06-27 | 1991-07-30 | Roche Holding Ltd. | Pyridine ethanolamine derivatives |
GB8703007D0 (en) * | 1987-02-10 | 1987-03-18 | Glaxo Group Ltd | Chemical compounds |
US5019578A (en) * | 1987-11-27 | 1991-05-28 | Merck & Co., Inc. | β-adrenergic agonists |
NZ226991A (en) * | 1987-11-27 | 1992-03-26 | Merck & Co Inc | Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors |
US5216170A (en) * | 1989-01-26 | 1993-06-01 | Bayer Aktiengesellschaft | (2-aminopropyl) pyridines useful as intermediates |
GB9209076D0 (en) * | 1992-04-27 | 1992-06-10 | Ici Plc | Chemical compounds |
EP0664788A1 (en) * | 1992-10-16 | 1995-08-02 | Byk Nederland BV | Substituted ethanolamine esters |
WO1994014775A1 (en) * | 1992-12-29 | 1994-07-07 | Smithkline Beecham Corporation | Platelet aggregation inhibiting compounds |
US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
AU6581294A (en) * | 1993-04-26 | 1994-11-21 | Fujisawa Pharmaceutical Co., Ltd. | Ethanolamine derivatives useful for the treatment of gastrointestinal disorders |
AU675536B2 (en) * | 1993-06-14 | 1997-02-06 | Pfizer Inc. | Secondary amines as antidiabetic and antiobesity agents |
JPH08165276A (en) * | 1994-12-14 | 1996-06-25 | Dainippon Pharmaceut Co Ltd | 2-akylamino-1-phenylethanol derivative |
-
1995
- 1995-05-10 JP JP8533903A patent/JPH11504649A/en active Pending
- 1995-05-10 EP EP95915995A patent/EP0824519A1/en not_active Ceased
- 1995-05-10 MX MX9708621A patent/MX9708621A/en not_active Application Discontinuation
- 1995-05-10 CA CA002220399A patent/CA2220399A1/en not_active Abandoned
- 1995-05-10 US US08/945,551 patent/US5977124A/en not_active Expired - Fee Related
- 1995-05-10 WO PCT/IB1995/000344 patent/WO1996035671A1/en not_active Application Discontinuation
-
1996
- 1996-05-02 IL IL11811596A patent/IL118115A0/en unknown
- 1996-05-03 TR TR96/00358A patent/TR199600358A2/en unknown
- 1996-05-07 CZ CZ961321A patent/CZ132196A3/en unknown
- 1996-05-07 SG SG1996009751A patent/SG43365A1/en unknown
- 1996-05-08 PL PL96314120A patent/PL314120A1/en unknown
- 1996-05-08 CO CO96022964A patent/CO4440567A1/en unknown
- 1996-05-09 AU AU52185/96A patent/AU706235B2/en not_active Ceased
- 1996-05-09 HU HU9601240A patent/HUP9601240A1/en unknown
- 1996-05-09 NZ NZ286548A patent/NZ286548A/en unknown
- 1996-05-09 KR KR1019960015262A patent/KR100190259B1/en not_active IP Right Cessation
- 1996-05-09 NO NO961887A patent/NO307049B1/en not_active IP Right Cessation
- 1996-05-10 BR BR9602209A patent/BR9602209A/en active Search and Examination
-
1997
- 1997-11-07 FI FI974172A patent/FI974172A/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO307049B1 (en) | 2000-01-31 |
NO961887D0 (en) | 1996-05-09 |
FI974172A0 (en) | 1997-11-07 |
JPH11504649A (en) | 1999-04-27 |
NZ286548A (en) | 1998-03-25 |
EP0824519A1 (en) | 1998-02-25 |
AU5218596A (en) | 1996-11-21 |
KR100190259B1 (en) | 1999-06-01 |
IL118115A0 (en) | 1996-09-12 |
KR960041168A (en) | 1996-12-19 |
HUP9601240A1 (en) | 1997-09-29 |
NO961887L (en) | 1996-11-11 |
TR199600358A2 (en) | 1996-11-21 |
BR9602209A (en) | 1998-04-07 |
SG43365A1 (en) | 1997-10-17 |
CZ132196A3 (en) | 1997-03-12 |
AU706235B2 (en) | 1999-06-10 |
CO4440567A1 (en) | 1997-05-07 |
WO1996035671A1 (en) | 1996-11-14 |
HU9601240D0 (en) | 1996-07-29 |
FI974172A (en) | 1997-11-07 |
CA2220399A1 (en) | 1996-11-14 |
US5977124A (en) | 1999-11-02 |
MX9708621A (en) | 1998-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL314120A1 (en) | B-adrenergic antagonists | |
HU9601176D0 (en) | Adhesion-receptor antagonists | |
AU6856796A (en) | Des-arg9-bk antagonists | |
GB9517098D0 (en) | Receptor | |
ZA96237B (en) | Substituted 2-pheylpyridines | |
ZA96238B (en) | Substituted 2-pheylpyridines | |
ZA969987B (en) | Lh-rh antagonists | |
HK1016175A1 (en) | Substituted phenyluracils | |
AP9600802A0 (en) | Libricant | |
GB9503380D0 (en) | Substituted azo-dicarbonylo deriratives | |
GB9506678D0 (en) | Substituted 6-azacholesten-3-ones | |
GB9507688D0 (en) | The thomobilizer | |
CA77215S (en) | Buoy | |
AU1105P (en) | DALESE Metrosideros excelsus | |
GB9514324D0 (en) | The multigame set | |
EP0726184A3 (en) | Shockabsorber | |
GB9513235D0 (en) | The keyblock | |
GB9505802D0 (en) | The teazer | |
GB9507334D0 (en) | The laddermaster | |
GB9502263D0 (en) | The spraymate | |
GB9519480D0 (en) | The maxi-lead | |
GB9515389D0 (en) | The Thingy | |
GB9518096D0 (en) | The stician | |
GB9518979D0 (en) | Mx - l i j | |
AU131279S (en) | Construction component |